Keratoacanthoma - Ceratoacanthoma
☆ AI Dermatology — Free Service
Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Ceratoacanthoma (Keratoacanthoma) benywaidd
relevance score : -100.0%
ReferencesMae Keratoacanthoma (KA) yn diwmor croen aml sy'n adnabyddus am ei dwf cyflym a'i botensial i atchweliad ar ei ben ei hun. Mae'n digwydd fel arfer mewn dynion hŷn, â chroen gweddol sydd â hanes o ddifrod gan yr haul. Er mai tynnu llawfeddygol gan ddefnyddio toriad neu lawdriniaeth ficrograffig Mohs yw'r driniaeth arferol, mae amryw o opsiynau therapi eraill ar gael.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Mae Keratoacanthoma (KA) yn tumor gradd isel sy'n dechrau mewn cyffro penodol ar y croen ac mae'n edrych yn debyg i squamous cell carcinoma (SCC) o dan microsgop. Mae'r dadl yn parhau ynghylch a ddylai KA gael ei ddosbarthu fel math o SCC ymledol.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) yw'r ail fath mwyaf cyffredin o ganser mewn pobl, yn enwedig ymhlith unigolion hŷn. Defnyddir llawdriniaeth fel arfer i drin cSCC, ond ar gyfer rhai cleifion na allant gael llawdriniaeth neu ddewis peidio, gellir ystyried opsiynau eraill fel triniaethau mewnanafiadol. Mae triniaethau mewnanafiadol traddodiadol (methotrexate or 5-fluorouracil) wedi'u defnyddio, ond mae ymchwil barhaus ar ddulliau newydd fel imiwnotherapi mewnanafiadol a firotherapi oncolytig. Yma, byddwn yn edrych ar wahanol driniaethau mewnanafiadol ar gyfer cSCC, yn amrywio o ddulliau clasurol i strategaethau blaengar.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
O dan y microsgop, mae ceratoacanthoma (keratoacanthoma) yn debyg iawn i garcinosoma celloedd cennog. Er bod rhai patholegwyr yn dosbarthu ceratoacanthoma (keratoacanthoma) fel endid ar wahân ac nid malaenedd, mae tua 6 % o ceratoacanthoma (keratoacanthoma) clinigol a histolegol yn symud ymlaen i ganserau celloedd cennog ymledol ac ymosodol.
○ Diagnosis a Thriniaeth
#Dermoscopy
#Skin biopsy